In this edition of our top stories, we will look into the transition process of the Canadian Agency for Drugs and Technologies in Health (CADTH) becoming the Canadian Drug Agency (CDA). We will also take a look at the 2023 update on Canadian Intellectual Property and Life Sciences Regulatory Law by Smart & Biggar's Rx IP Team. These stories are gathered through our full-spectrum monitoring, leveraging both AI and human knowledge.
In a recent announcement on December 18, 2023, the federal government revealed plans for a significant transformation of the CADTH into the CDA. The CDA will deliver the dedicated leadership and coordination required to make Canada's drug system more sustainable and future-ready, therefore assisting Canadians in achieving better health outcomes. This change, as highlighted by CADTH in their statement, is viewed as an opportunity to leverage the trust built within the pan-Canadian drugs and devices environment.
As the CDA is established, CADTH will expand its expertise and role in the pharmaceutical sector while continuing to engage in other areas like health technology assessment and post-market safety and effectiveness.
In keeping with this transformative time, the Rx IP Team of Smart & Biggar, regarded as Canada’s leading firm for intellectual property, released a comprehensive 2023 update offering a meticulous analysis of Canadian intellectual property and life sciences regulatory law.
Their report provided in-depth insights into patent decisions, pivotal court rulings concerning the Patented Medicines (Notice of Compliance) Regulations, amendments to the Patent Act introducing patent term adjustment, and updates regarding the Patented Medicine Prices Review Board. Furthermore, it covered significant subjects like the National Strategy for Rare Diseases, Health Canada's regulatory initiatives, and improvements made in reimbursement reviews by the CADTH.
In other news, AI-powered systems like CHARTWatch, an early-warning AI algorithm developed at St. Michael's that examines 100 variables in a patient's file, including lab results and vital signs, and assesses whether the patient is at a low, moderate, or high risk of requiring ICU care within the next 24 hours, are proving impactful in revolutionizing healthcare, The Globe and Mail reported.
Dr. Yuna Lee, a hospital physician, highlighted CHARTWatch's ability to spot a patient's condition before obvious signs show up. After a 20-month study, St. Michael’s saw a 26% decrease in the risk of non-palliative patient deaths post CHARTWatch's launch, showcasing AI's crucial role in healthcare innovation.
Despite these positive outcomes, there are concerns among healthcare experts about Canada's slow uptake of AI in healthcare, which might slow down progress and innovation in medical practices and diagnostics.Top of Form
AI integration in Canadian hospitals encounters challenges including funding, privacy issues, and the need to improve AI accuracy. Currently, AI assists medical professionals instead of replacing them, supporting tasks like note-taking and patient interactions.
Our clients receive these kinds of stories daily, granting them the opportunity to keep up with the latest trends. If you want to know how our full-spectrum monitoring works, book a free consultation with us today!
